Affiliation:
1. Department of Dermatology and Allergy Copenhagen University Hospital – Herlev and Gentofte Copenhagen Denmark
2. Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
Abstract
AbstractWhether clinical and genetic markers can be used to differentiate patients with varying responses to different psoriasis therapies needs to be elucidated. Here, we assess whether human leukocyte antigen C (HLA‐C)*06:02 is associated with response to biologics. Response to treatment was defined as a Psoriasis Area and Severity Index score of ≤2 (PASI≤ 2) after 3 months. In total, 648 patients with psoriasis initiating treatment with biologics were included; 289 were HLA‐C*06:02 positive and 359 were HLA‐C*06:02 negative. Patients were treated with tumor necrosis factor (TNF) inhibitors (n = 469), interleukin (IL)‐12/23 inhibitors (n = 92), IL‐17 inhibitors (n = 78), and IL‐23 inhibitors (n = 9). Significantly more patients positive for HLA‐C*06:02 achieved PASI≤ 2 compared with patients negative for HLA‐C*06:02 when treated with IL‐12/23 inhibitors. There was no significant difference between response in HLA‐C*06:02 positive and negative patients for TNF inhibitors or IL‐17 inhibitors. No analyses were conducted for IL‐23 inhibitors because of the limited number of patients. The data confirm that HLA‐C*06:02 may be used as a biomarker for response to anti‐IL12/23 treatment.